metoclopramide has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metoclopramide treatment reduces murine and human LSCs in vitro and prolongs survival of chronic myeloid leukemia (CML) mice through downregulation of pathways related to stemness and proliferation in LSCs." | 1.62 | Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells. ( Albers, CE; Arambasic, M; Bachmann, C; Baerlocher, GM; Bürgin, DT; Hoppe, S; Kallen, NM; Lüthi, U; Ochsenbein, AF; Radpour, R; Riether, C; Schürch, CM, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Riether, C | 1 |
| Radpour, R | 1 |
| Kallen, NM | 1 |
| Bürgin, DT | 1 |
| Bachmann, C | 1 |
| Schürch, CM | 1 |
| Lüthi, U | 1 |
| Arambasic, M | 1 |
| Hoppe, S | 1 |
| Albers, CE | 1 |
| Baerlocher, GM | 1 |
| Ochsenbein, AF | 1 |
1 other study available for metoclopramide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells.
Topics: Animals; Dopamine D2 Receptor Antagonists; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 2021 |